Sun Pharma Advanced Research Company is currently trading at Rs. 167.75, up by 5.25 points or 3.23% from its previous closing of Rs. 162.50 on the BSE.
The scrip opened at Rs. 163.50 and has touched a high and low of Rs. 169.60 and Rs. 163.40 respectively. So far 93489 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 217.25 on 13-Dec-2018 and a 52 week low of Rs. 107.00 on 09-Jul-2019.
Last one week high and low of the scrip stood at Rs. 169.60 and Rs. 150.70 respectively. The current market cap of the company is Rs. 4395.85 crore.
The promoters holding in the company stood at 68.46%, while Institutions and Non-Institutions held 4.27% and 27.26% respectively.
Sun Pharma Advanced Research Company’s (SPARC) patent infringement complaint regarding its New Drug Application for Taclantis injection PICS (Paclitaxel Injection Concentrate for Suspension) has been withdrawn by Abraxis Bioscience LLC. The company will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay.
Earlier, Abraxis Biosciences LLC has filed a complaint against the company in the US District Court for the district of New Jersey. It alleged that the SPARC’s filing of New Drug Application (NDA) for Taclantis injection (Paclitaxel Injection Concentrate for Suspension) is an act of infringement of the Orange Book listed patents for Abraxane.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 435.70 |
| Indegene | 486.80 |
| CMS Info Systems | 318.00 |
| JITF Infralogistics | 338.00 |
| Sagility | 42.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: